Transgenic Mouse Facility

转基因小鼠设施

基本信息

批准号：
7714128
负责人：
THEODORE G KRONTIRIS
金额：
$ 3.55万
依托单位：
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-09-01 至 2012-11-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7714128
关键词：
Biological Models Budgets Cancer Center Cancer Center Support Grant Cancer Etiology Cells Chimera organism Cities Consult Cryopreservation Cutaneous DNA DNA Library Electroporation Embryo Embryo Transfer Etiology Excision Experimental Designs Facility Construction Funding Category Fees Freezing Funding Future Gene Mutation Gene Targeting Genetic Materials Genome Genomics Goals Human In Vitro Institution Knock-in Mouse Knock-out Knockout Mice Label Laboratory mice Lentivirus Vector Microinjections Modeling Modification Molecular Mouse Strains Mus Numbers Peer Review Physiological Plasmids Production Range Recombinants Reporting Research Research Personnel Resource Sharing Role Services Shared Resource Cancer Center Standards of Weights and Measures System Techniques Technology Testing Tissues Transgenes Transgenic Mice Transgenic Mouse Facility Transgenic Organisms Update Xenograft Model base cancer therapy cancer type embryonic stem cell gain of function gene function human disease improved in vivo Model member mouse genome pathogen programs research study tool vector zygote

项目摘要

The goal of the Transgenic/knock-out Mouse Core (TMC) is to produce genetically modified mice as in vivo models for exploring the normal function of genes, and the role of genetic mutations in the etiology and treatment of cancer. The range of modifications that can be introduced into the genome of the laboratory mouse include integration of exogenous DMA (transgenes) useful in gain-of-function and cell labeling, and the precise excision (knock-out) or alteration (knock-in) of gene function that can be controlled both tissuespecifically and temporally. Transgenic and knock-in/knock-out mice are often the logical extension of studies initiated in vitro, and provide a model system with greater anatomical and physiological relevance to human disease. Genetically modified mice have been essential tools in elucidating the molecular underpinnings of many types of cancer, and supplement the traditional sub-cutaneous xenograft model for testing new anti-cancer therapies. During the most recent 12-month reporting period (January 2005 to December 2005) nine Cancer Center members from 3 programs and one non-aligned member used the transgenic/knock-out mouse shared resource. The number of users with peer-reviewed funding represented 66% of users overall. Annual budget for the core is $269,657, with 68% from the institution, 13% from user fees, and 19% ($50,000) requested from the CCSG.

转基因/基因敲除小鼠核心（TMC）的目标是生产体内转基因小鼠用于探索基因正常功能以及基因突变在病因和疾病中的作用的模型癌症的治疗。可以引入实验室基因组的修饰范围小鼠包括外源 DMA（转基因）的整合，可用于功能获得和细胞标记，以及可以特异性控制两个组织的基因功能的精确切除（敲除）或改变（敲入）和暂时的。转基因和敲入/敲除小鼠通常是逻辑延伸在体外启动的研究，并提供了一个具有更大解剖学和生理学相关性的模型系统人类疾病。转基因小鼠已成为阐明分子生物学的重要工具许多类型癌症的基础，并补充传统的皮下异种移植模型测试新的抗癌疗法。在最近 12 个月的报告期内（2005 年 1 月至 2005 年 12 月）来自 3 个项目的 9 名癌症中心成员和 1 名不结盟成员使用了转基因/基因敲除小鼠共享资源。获得同行评审资金的用户数量占总体用户的 66%。核心年度预算为 269,657 美元，其中 68% 来自机构，13% 来自用户费，以及向 CCSG 请求的 19%（50,000 美元）。